The pharmacology and toxicology of polyphenolic-glutathione conjugates

Annual Review of Pharmacology and Toxicology

Volumn 38, Issue , 1998, Pages 229-255

  Monks, Terrence J ^a   Lau, Serrine S ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Chemical induced stress response; DNA damage and gene expression; Growth arrest; Physiological barriers; Quinol thioethers

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE DERIVATIVE; POLYPHENOL DERIVATIVE;

BLOOD TOXICITY; CARCINOGENICITY; DRUG CONJUGATION; DRUG MECHANISM; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; TOXICOLOGY;

EID: 0031777186     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.38.1.229     Document Type: Review

References (187)

1. Thompson RH. 1971. Naturally Occurring Quinones. London: Academic
2. Monks TJ, Walker SE, Flynn LM, Conti CJ, DiGiovanni J. 1990. Epidermal ornithine decarboxylase induction and mouse skin tumor promotion by quinones. Carcinogenesis 11:1795-801
3. Schuetzle D, Lee S-C, Prater TJ, Tejada SB. 1981. Polynuclear aromatic hydrocarbon (PAH) derivatives in mutagenic fractions of diesel particulate extracts. Int. J. Environ. Anal. Chem. 9:93-144
4. Schuetzle D. 1983. Sampling of vehicle emissions for chemical analysis and biological testing. Environ. Health Perspect. 47:65-80
5. Ames BN. 1983. Dietary carcinogens and anticarcinogens. Science 221:1256-64
6. Chesis PL, Levin DE, Smith MT, Ernster L, Ames BN. 1984. Mutagenicity of quinones: pathways of metabolic activation and detoxification. Proc. Natl. Acad. Sci. USA 81:1696-700
7. Jeftic L, Manning G. 1970. A survey on the electrochemical reduction of quinones. J. Electroanal. Chem. 26:195-200
8. Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG. 1992. Contemporary issues in toxicology. Quinone chemistry and toxicity. Toxicol. Appl. Pharmacol. 112:2-16
9. Reed DJ, Meredith MJ. 1985. Cellular defense mechanisms against reactive metabolites. In Bioactivation of Foreign Compounds, ed. MW Anders, pp. 71-108. New York: Academic
10. Monks TJ, Lau SS. 1992. Toxicology of quinone-thioethers. CRC Crit. Rev. Toxicol. 22:243-70
11. Monks TJ, Lau SS. 1994. Glutathione conjugate mediated toxicities. In Handbook of Experimental Pharmacology. Vol. 112. Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity, ed. FC Kauffman, pp. 459-509. Berlin: Springer-Verlag
12. Monks TJ, Lau SS. 1994. Glutathione conjugation as a mechanism for the transport of reactive metabolites. In Advances in Pharmacology. Vol. 27. Conjugation-Dependent Carcinogenicity and Toxicology of Foreign Compounds, ed. MW Anders, W Dekant, pp. 183-210. New York: Academic
13. Monks TJ, Lau SS. 1997. Biological reactivity of polyphenolic-glutathione conjugates. Chem. Res. Toxicol. 10: 1296-1313
14. Monks TJ, Lau SS, Highet RJ, Gillette JR. 1985. Glutathione conjugates of 2-bromohydroquinone are nephrotoxic. Drug Metab. Dispos. 13:553-59
15. Monks TJ, Highet RJ, Lau SS. 1988. 2-Bromo-(diglutathion-S-yl) hydroquinone nephrotoxicity. Physiological, biochemical and electrochemical determinants. Mol. Pharmacol. 34:492-500
16. Lau SS, Hill B, Highet RJ, Monks TJ. 1988. Sequential oxidation and glutathione addition to 1,4-benzoquinone: correlation of toxicity with increased glutathione substitution. Mol. Pharmacol. 34:829-36
17. Peters MM, Jones TW, Monks TJ, Lau SS. 1996. Glutathione conjugates of 2-tert-butylhydroquinone, metabolites of the renal tumor promoter tert-butylhydroxyanisole, are toxic to kidney and bladder. Cancer Res. 56:1006-11
18. Butterworth M, Lau SS, Monks TJ. 1998. 2-Hydroxy-4-glutathion-S-yl-17 β-estradiol and 2-hydroxy-1-glutathion-S-yl-17β-estradiol produce oxidative stress and renal toxicity in an animal model of 17β-estradiol-mediated nephrocarcinogenicity. Carcinogenesis 19:In press
19. Rivera MI, Jones TW, Lau SS, Monks TJ. 1994. Early morphological and biochemical changes during 2-bromo-(diglutathion-S-yl) hydroquinone-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 128:239-50
20. Hill BA, Monks TJ, Lau SS. 1992. The effects of 2,3,5-(triglutathion-S-yl)hydroquinone on renal mitochondrial respiratory function in vivo and in vitro. Possible role in cytotoxicity. Toxicol. Appl. Pharmacol. 117:165-71
21. Mertens JJWM, Gibson NW, Lau SS, Monks TJ. 1995. Reactive oxygen species and DNA damage in 2-bromo-(glutathion-S-yl)hydroquinone mediated cytotoxicity. Arch. Biochem. Biophys. 320:51-58
22. Jeong JK, Stevens JL, Lau SS, Monks TJ. 1996 Quinone-thioether-mediated DNA damage, growth arrest, and gadd153 expression in renal proximal tubular epithelial cells. Mol. Pharmacol. 50:592-98
23. Jeong JK, Dybing E, Söderlund E, Brunborg G, Holme JA, et al. 1997. DNA damage, gadd153 expression, and cytotoxicity in plateau phase renal proximal tubular epithelial cells treated with a quinol-thioether. Arch. Biochem. Biophys. 341:300-8
24. Fornace AJ Jr, Nebert DW, Hollander MC, Luethy JD, Papathanasiou M, et al. 1989. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol. Cell. Biol. 9:4196-203
25. Ron D, Habener JF. 1992. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factor C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev. 6:439-53
26. Leuthy JD, Fargnoli J, Park JS, Fornace AJ Jr, Holbrook NJ. 1990. Isolation and characterization of the hamster gadd153 gene. Activation of promoter activity by agents that damage DNA. J. Biol. Chem. 265:16521-26
27. Chen Q, Yu K, Holbrook NJ, Stevens JL. 1992. Activation of the growth and DNA damage-inducible gene gadd153 by nephrotoxic cysteine conjugates and dithiothreitol. J. Biol. Chem. 267:8207-12
28. Graham DG, Tye R, Vogel FS. 1977. Inhibition of DNA polymerase from L1210 murine leukemia cells by a sulfhydryl reagent from Agaricus bisporus. Cancer Res. 37:436-39
29. Wick MM, Rosowsky A, Ratcliff J. 1980. Antitumor effects of L-glutamic acid dihydroxyanilides against experimental melanoma. J. Invest. Dermatol. 74:112-14
30. Fitzgerald GB, Wick MM. 1983. 3,4-Dihydroxybenzylamine: an improved dopamine analog cytotoxic for melanoma cells in part through oxidation products inhibitory to DNA polymerase. J. Invest. Dermatol. 80:119-23
31. Prezioso JA, Wang N, Bloomer WD. 1992. Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminyl-phenol. Cancer Chemother. Pharmacol. 30:394-400
32. Fitzgerald GB, Wick MM. 1985. Inhibition of ribonucleotide reductase by antitumor agents related to levodopa and dopamine. Biochem. Pharmacol. 34:353-60
33. Jeong JK, Lau SS, Monks TJ. 1997 The response of renal epithelial cells to physiological- and chemical-induced growth arrest. J. Biol. Chem. 272:7511-18
34. Hayes JJ, Wolffe AP. 1992. Histones H2A/H2B inhibit the interaction of transcription factor IIIA with the Xenopus borealis somatic 5S RNA gene in a nucleosome. Proc. Natl. Acad. Sci. USA 89:1229-33
35. Tremethick D, Zucker K, Worcel A. 1990. The transcription complex of the 5 S RNA gene, but not transcription factor IIIA alone, prevents nucleosomal repression of transcription. J. Biol. Chem. 265:5014-23
36. Marzluff WF, Hanson RJ. 1993. In Control of Messenger RNA Stability, ed. J Belasco, G Brawerman, pp. 267-90. San Diego: Academic
37. Peltz SW, Ross J. 1987. Autogenous regulation of histone mRNA decay by histone proteins in a cell-free system. Mol. Cell Biol. 7:4345-56
38. McLaren RS, Ross J. 1993. Individual purified core and linker histones induce histone H4 mRNA destabilization in vitro. J. Biol. Chem. 268:14637-44
39. Landsberger N, Ranjan M, Almouzni G, Stump D, Wolffe AP. 1995. The heat shock response in Xenopus oocytes, embryos, and somatic cells: a regulatory role for chromatin. Dev. Biol. 170:62-74
40. Bradbury EM. 1992. Reversible histone modifications and the chromosome cell cycle. BioEssays 14:9-16
41. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. 1977. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268:462-64
42. Yoshida M, Kijima M, Akita M, Beppu T. 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. biol. Chem. 265:17174-79
43. Lee DY, Hayes JJ, Pruss D, Wolffe AP. 1993. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72:73-84
44. Almouzni G, Khochbin S, Dimitrov S, Wolffe AP. 1994. Histone acetylation influences both gene expression and development of Xenopus laevis. Dev. Biol. 165:654-69
45. Arts J, Lansink M, Grimbergen J, Toet KH, Kooistra T. 1995. Stimulation of tissue-type plasminogen activator gene expression by sodium butyrate and trichostatin A in human endothelial cells involves histone acetylation. Biochem. J. 310:171-76
46. Gupta S, Alpini G, Vemuru RP, Hurston E, Shafritz DA. 1994. Butyrate synchronization of hepatocytes: modulation of cycling and cell cycle regulated gene expression. Growth Factors 10:171-80
47. Miyashita T, Yamamoto H, Nishimune Y, Nozaki, M, Morita T, et al. 1994. Activation of the mouse cytokeratin A (endo A) gene in teratocarcinoma F9 cells by the histone deacetylase inhibitor Trichostatin A. FEBS Lett. 353:225-29
48. 3H]-staurosporine on various protein kinases. Biochem. Biophys. Res. Commun. 171:189-95
49. Gadbois DM, Hamaguchi JR, Swank RA, Bradbury EM. 1992. Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem. Biophys. Res. Commun. 184:80-85
50. Th'ng JPH, Guo X-W, Swank RA, Crissman HA, Bradbury EM. 1994. Inhibition of histone phosphorylation by staurosporine leads to chromosome decondensation. J. Biol. Chem. 269:9568-73
51. Crissman HA, Gadbois DM, Tobey RA, Bradbury EM. 1991. Multiple kinase arrest points in the G1 phase of nontransformed mammalian cells are absent in transformed cells. Proc. Natl. Acad. Sci. USA 88:7580-84
52. Abe K, Yoshida M, Usui T, Horinouchi S, Beppu T. 1991. Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. Exp. Cell Res. 192:122-27
53. Hill BA, Kleiner HE, Ryan EA, Dulik DM, Monks TJ, et al. 1993. Identification of multi-S-substituted conjugates of hydroquinone by HPLC-coulometric electrode array analysis and mass spectroscopy. Chem. Res. Tox. 6:459-69
54. Peters MM, Lau SS, Dulik DM, Murphy D, van Ommen B, et al. 1996. Metabolism of 2-tert-butylhydroquinone to S-substituted conjugates in the male Fischer 344 rat. Chem. Res. Toxicol. 9:133-39
55. Butterworth M, Lau SS, Monks TJ. 1997. Metabolism and mild nephrotoxicity of 17β-estradiol in the golden Syrian hamster. Formation of catechol estrogen glutathione conjugates and implications for 17β-estradiol-mediated nephrocarcinogenicity. Carcinogenesis 18:561-67
56. Thompson EM, Legouy E, Christians E, Renard JP. 1995. Progressive maturation of chromatin structure regulates HSP70.1 gene expression in the preimplantation mouse embryo. Development 121:3425-37
57. Baeuerle PA. 1995. Inducible Gene Expression. Vol. 1. Environmental Stresses and Nutrients. Boston: Birkhäuser
58. Walker GC. 1984. Mutagenesis and inducible response to deoxyribonucleic acid damage in Escherichia coli. Microbiol. Rev. 48:60-93
59. Walker GC. 1985. Inducible DNA repair systems. Annu. Rev. Biochem. 54:425-57
60. Storz G, Tartaglia LA, Ames BN. 1990. Transcriptional regulation of oxidative stress-inducible genes: direct activation by oxidation. Science 248:189-94
61. Lindahl T, Sedwick B, Sekigychi M, Nakabeppu Y. 1988. Regulation and expression of the adaptive response to alkylating agents. Annu. Rev. Biochem. 57:133-57
62. Ouellette AJ, Malt RA, Sukhatme VP, Bonventre JV. 1990. Expression of two "immediate early" genes, Egr-1 and c-fos, in response to renal ischemia and during compensatory renal hypertrophy in mice. J. Clin. Invest. 85:766-71
63. Wyllie AH, Rese KA, Morris RG, Steel CM, Foster CM, et al. 1987. Rodent fibroblast tumors expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Br. J. Cancer. 56:251-59
64. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. 1991. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915-22
65. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, et al. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-28
66. 2+] in induction of c-fos, c-jun, and c-myc mRNA in rat PTE after oxidative stress. FASEB J. 6:919-24
67. Chen Q, Ames BN. 1994. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc. Natl. Acad. Sci. USA 91:4130-34
68. Shibanuma M, Arata S, Murata M, Nose K. 1995. Activation of DNA synthesis and expression of the JE gene by catalase in mouse osteoblastic cells: possible involvement of hydrogen peroxide in negative growth regulation. Exp. Cell Res. 218:132-36
69. Luethy JD, Holbrook NJ. 1992. Activation of the gadd153 promoter by genotoxic agents: a rapid and specific response to DNA damage. Cancer Res. 52:5-10
70. Fornace AJ Jr. 1992. Mammalian genes induced by radiation. Activation of genes associated with growth control. Annu. Rev. Genet. 26:507-26
71. Ohba M, Shibanuma M, Kuroki T, Nose K. 1994. Production of hydrogen peroxide by transforming growth factor-beta 1 and its involvement in induction of egr-1 in mouse osteoblastic cells. J. Cell Biol. 126:1079-88
72. Schreck R, Albermann K, Baeuerle PA. 1992. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells. Free Rad. Res. Commun. 17:221-37
73. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secoodary antioxidant-responsive factor. EMBO J. 12:2005-18
74. Guy GR, Cairns J, Ng SB, Tan YH. 1993. Inactivation of a redox-sensitive phosphatase during the early events of tumor necrosis factor/interleukin-1 signal transduction. J. Biol. Chem. 268:2141-48
75. Devary Y, Gottlieb RA, Smeal T, Karin M. 1992. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 71:1081-91
76. Shibanuma M, Kuroki T, Nose K. 1990. Stimulation by hydrogen peroxide of DNA synthesis, competence family gene expression and phosphorylation of a specific protein in quiescent Balb/3T3 x cells. Oncogene 5:1025-32
77. Djuric Z, Everett CK, Luongo D. 1993. Toxicity, single-strand breaks, and 5-hydroxymethyl-2′-deoxyuridine formation in human breast epithelial cells treated with hydrogen peroxide. Free Rad. Biol. Med. 14:541-47
78. Powis G, Briehl M, Oblong J. 1995. Redox signalling and the control of cell growth and death. Pharmacol. Ther. 68:149-73
79. Luethy JD, Holbrook NJ. 1994. The pathway regulating GADD153 induction in response to DNA damage is independant of protein kinase C and tyrosine kinase. Cancer Res. 54:1902s-6s (Suppl.)
80. Testa U, Pelosi E, Peschle C. 1993. The transferrin receptor. Crit. Rev. Oncol. 4:241-76
81. Elledge SJ, Zhou Z, Allen JB. 1992. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biol. Sci. 17:119-23
82. Fox RM. 1985. Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase. Pharmacol. Ther. 30: 31-42
83. Terada N, Or R, Szepesi A, Lucas JJ, Gelfand EW. 1993. Definition of the roles for iron and essential fatty acids in cell cycle progression of normal human T lymphocytes. Exp. Cell Res. 204:260-67
84. van Dolah FM, Ramsdell JS. 1996. Maitotoxin, a calcium channel activator, inhibits cell cycle progression through the G1/S and G2/M transitions and prevents CDC2 kinase activation in GH4C1 cells. J. Cell Physiol. 166:49-56
85. cdc2 kinase activation in serum-stimulated human fibroblasts. J. Biol. Chem. 268:138-45
86. Linke SP, Clarkin KC, Leonardo AD, Tsou A, Wahl GM. 1996. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10:934-47
87. Wice BM, Reitzer LJ, Kennel D. 1981. The continuous growth of vertebrate cells in the absence of sugar. J. Biol. Chem. 256:7812-19
88. Reitzer LJ, Wice BM, Kennel D. 1979. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254:2669-76
89. Cole LA, Scheid JM, Tannen, RL. 1986. Induction of mitochondrial metabolism and pH-modulated ammoniagenesis by rocking LLC-PK1 cells. Am. J. Physiol. 251:C293-98
90. Ichimura T, Finch PW, Zhang G, Kan M, Stevens JL. 1996. Induction of FGF-7 after kidney damage: a possible paracrine mechanism for tubule repair. Am. J. Physiol. 271(40):F967-76
91. Hammerman MR, Oshea M, Miller SB. 1993. Role of growth factors in regulation of renal growth. Annu. Rev. Physiol. 55:305-21
92. Schaudies RP, Nonclercq D, Nelson L, Toubeau G, Zanen J, et al. 1993. Endogenous EGF as a potential renotrophic factor in ischemia-induced acute renal failure. Am. J. Physiol. 265(34):F425-34
93. Verstrepen WA, Nouwen EJ, Yue XS, DeBroe ME. 1993. Altered growth factor expression during toxic proximal tubular necrosis and regeneration. Kidney Int. 43:1267-79
94. Choi AM, Fargnoli J, Carlson SG, Holbrook NJ. 1992. Cell growth inhibition by prostaglandin A2 results in elevated expression of gadd153mRNA. Exp. Cell Res. 199:85-89
95. 1 cells by β-lyase-dependent and independent nephrotoxicants. Fund. Appl. Toxicol. 36:161-62 (Abstr.)
96. 2-mediated cytoprotection in renal epithelial cells. Evidence for a pharmacologically distinct receptor. Am. J. Physiol. 273(42):F507-15
97. Cho A, Segal DS. 1994. Amphetamine and its Analogs. Psychopharmacology. Toxicology, and Abuse. San Diego: Academic
98. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C. 1985. Hallucinogenic amphetamine selectively destroys brain serotonergic nerve terminals. Science 229:986-88
99. Commins DL, Vosmer G, Virus R, Woolverton W, Schuster C, Seiden L. 1987. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in rat brain. J. Pharmacol. Exp. Ther. 241:338-45
100. Ricaurte GA, DeLanney LE, Irwin I, Langston JW. 1988. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 446:165-68
101. Fuller RW. 1976. Pharmacology of p-chloroamphetamine and analogs. Psychopharmacol. Bull. 12:55-57
102. Ricaurte GA, Martello AL, Katz JL, Martello MB. 1992. Lasting effects of 3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J. Pharmacol. Exp. Ther. 261:616-22
103. Axt KJ, Mullen CA, Molliver ME. 1992. Cytopathologic features indicitive of 5-hydroxytryptamine axon degeneration are observed in rat brain after administration of D- and L-methylenedioxyamphetamine. Ann. NY Acad. Sci. 648:245-47
104. Deleted in proof
105. Schmidt CJ, Taylor VL. 1988. Direct central effects of acute methylenedioxymerhamphetamine on serotonergic neurons. Eur. J. Pharmacol. 156:121-31
106. Lin L, Kumagai Y, Cho AK. 1992. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem. Res. Toxicol. 5:401-6
107. Kumagai Y, Wickham KA, Schmitz DA, Cho AK. 1991. Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations. Biochem. Pharmacol. 42:1061-67
108. Midha KK, Hubbard JW, Bailey K, Cooper JK. 1978. α-Methyldopamine, a key intermediate in the metabolic disposition of 3,4-methylenedioxyamphetamine in vivo in dog and monkey. Drug Metab. Dispos. 6:623-30
109. Lim HK, Foltz RL. 1988. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem. Res. Toxicol. 1:370-78
110. Hiramatsu M, Kumagai Y, Unger SE, Cho AK. 1990. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther. 254:521-27
111. Kumagai Y, Lin L, Schmitz DA, Cho AK. 1991. Hydroxyl radical mediated demethylenation of (methylenedioxy)phenyl compounds. Chem. Res. Toxicol. 4:330-34
112. McCann UD, Ricaurte GA. 1991. Major metabolites of (±)-3,4-methylenedioxyamphelamine (MDA) do not mediate its toxic effects on brain serotonin neurons. Brain Res. 545:279-82
113. Johnson M, Elayan I, Hanson GR, Foltz RL, Gibb JW, Lim HK. 1992. Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxyamphelamine, on central serotonergic and dopaminergic systems. J. Pharmacol. Exp. Ther. 261:447-53
114. Zhao Z, Castagnoli N Jr, Ricaurte GA, Steele T, Martello M. 1992. Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)-methamphetamine]. Chem. Res. Toxicol. 5:89-94
115. Deleted in proof
116. Patel N, Kumagai Y, Unger SE, Cho AK. 1991. Transformation of dopamine and α-methyldopamine by NG-108-15 cells: formation of thiol adducts. Chem. Res. Toxicol. 4:421-26
117. Kannan R, Kuhlenkamp JF, Jeandidier E, Trinh H, Ookhtens M, et al. 1990. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J. Clin. Invest. 85:2009-13
118. Jackson MA, Lyon JP, Siegel J. 1971. Morphological changes in kidneys of rats exposed to dichloroacetylene-ether. Toxicol. Appl. Pharmacol. 18:175-84
119. Reichert D, Liebaldt G, Henschler D. 1976. Neurotoxic effects of dichloroacetylene. Arch. Toxicol. 37:23-38
120. Patel N, Fullone JS, Anders MW. 1993. Brain uptake of S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine, the glutathione and cysteine S-conjugates of the neurotoxin dichloroacetylene. Mol. Brain Res. 17:53-58
121. Deleted in proof
122. Miller RT, Lau SS, Monks TJ. 1996. Effects of 5-(glutathion-S-yl)-α-methyldopamine on dopamine, serotonin, and norepinephrine concentrations following intracerebroventricular administration to male Sprague-Dawley rats. Chem. Res. Toxicol. 9:457-65
123. Stone DM, Johnson M, Hanson GR, Gibb JW. 1988. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 247:79-87
124. Brodkin J, Malyala A, Nash JF. 1993. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol. Biochem. Behav. 45:647-53
125. Miller RT, Lau SS, Monks TJ. 1995. Metabolism of 5-(glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem. Res. Toxicol. 8:634-41
126. Miller RT, Lau SS, Monks TJ. 1997. 2,5-bis-(Glutathion-S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, produces long-term decreases in brain serotonin concentrations. Eur. J. Pharmacol. 323:173-80
127. Hill BA, Lo H, Monks TJ, Lau SS. 1990. The role of γ-glutamyl transpeptidase in hydroquinone-glutathione conjugate mediated nephrotoxicity. In Biological Reactive Intermediates IV, ed. CM Witmer, RR Snyder, DJ Jollow, GF Kalf, JJ Kocsis, IG Sipes, pp. 749-51. New York: Plenum
128. Ploemen JHTM, van Ommen B, De Haan A, Venekamp JC, van Bladeren PJ. 1994. Inhibition of human glutathione S-transferases by dopamine, α-methyldopa and their 5-S-glutathionyl conjugates. Chem.-Biol. Interact. 90:78-99
129. 3H]-glutathione in rat central and peripheral tissues. Neurochem. Int. 13:493-97
130. Zangerle L, Cuenod M, Winterhalter KH, Do KQ. 1990. Screening of thiol compounds: depolarization-induced release of glutathione and cysteine from rat brain slices. J. Neurochem. 59:181-89
131. Leslie SW, Brown LM, Trent RD, Lee Y-H, Morris JL, et al. 1992. Stimulation of N-methyl-D-aspartate receptor-mediated calcium entry into dissociated neurons by reduced and oxidized glutathione. Mol. Pharmacol. 41:308-14
132. Liu YF, Quirion R. 1992. Modulatory role of glutathione on μ-opioid, substance P/neurokinin 1, and kainic acid receptor binding sites. J. Neurochem. 59:1024-32
133. Kubo E, Horiuchi T, Nakamura A, Shiomi H. 1992. Potent antinociceptive effects of centrally administered glutathione and glutathione-disulfide in mice. Jpn. J. Pharmacol. 58(Suppl. 1): 311
134. Guo N, Mcintosh C, Shaw C. 1992. Glutathione; new candidate neuropeptide in the central nervous system. Neuroscience 4:835-42
135. Pileblad E, Magnusson T, Fornstedt B. 1989. Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxy-dopamine in rat striatum. J. Neurochem. 52:978-80
136. Strupp M, Quasthoff N, Mitrovic N, Grafe P. 1992. Glutathione accelerates sodium channel inactivation in excised rat axonal membrane patches. Eur. J. Physiol. 421:283-85
137. Subrahmanyam VV, Kolachana P, Smith MT. 1991. Metabolism of hydroquinone by human myeloperoxidase: mechanisms of stimulation by other phenolic compounds. Arch. Biochem. Biophys. 286:76-84
138. Subrahmanyam VV, Ross D, Eastmond DA, Smith MT. 1991. Potential role of free radicals in benzene-induced myelotoxicity and leukemia. Free Radic. Biol. Med. 11:495-515
139. Thomas DJ, Sadler A, Subrahmanyam VV, Siegel D, Reasor MJ, et al. 1991. Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone: comparison of macrophages and fibroblastoid cells. Mol. Pharmacol. 37:255-62
140. Kariya K, Lee EW, Hirouchi M, Hosokawa M, Sayo M. 1987. Purification and some properties of peroxidases of rat bone marrow. Biochem. Biophys. Acta. 99:95-101
141. Humes JL, Bonney RJ, Pelus L, Dahlgren ME, Sadowski SJ, et al. 1977. Macrophages synthesize and release prostaglandins in response to inflammatory stimuli. Nature 269:149-51
142. Bratton SB, Lau SS, Monks TJ. 1997. Identification of quinol-thioethers in bone marrow of hydroquinone/phenol treated rats and mice, and their potential role in benzene-mediated hematotoxicity. Chem. Res. Toxicol. 10:859-65
143. Snyder CA, Goldstein BD, Sellakumar A, Wolman SR, Bromberg I, et al. 1978. Hematotoxicity of inhaled benzene to Sprague-Dawley rats and AKR mice at 300 ppm. J. Toxicol. Environ. Health 4:605-18
144. Groopman JE, Molina JN, Scadden DT. 1989. Hematopoietic growth factors. Biology and clinical applications. N. Engl. J. Med. 321:1449-59
145. Blanchard KL, Acquaviva AM, Galson DL, Bunn HF. 1992. Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol. Cell Biol. 12:5373-85
146. Kalf GF, Renz JF, Nicolescu R. 1996. p-Benzoquinone, a reactive metabolite of benzene, prevents the processing of pre-interleukins -1α and -1β to active cytokines by inhibition of the processing enzymes, calpain, and the interleukin - 1β converting enzyme. Environ. Health Perspect. 104(Suppl. 6):1251-56
147. Platanias LC, Vogelzang NJ. 1990. Interleukin-1: biology, pathophysiology, and clinical prospects. Am. J. Med. 89:621-29
148. Niculescu R, Kalf GF. 1995. A morphological analysis of the short-term effects of benzene on the development of the hematological cells in the bone marrow of mice and the effects of interleukin-1a on the process. Arch. Toxicol. 69:141-48
149. Dempster AM, Snyder CA. 1990. Short-term benzene exposure provides a growth advantage for granulocytic progenitor cells over erythroid progenitor cells. Arch. Toxicol. 64:539-44
150. Irons RD, Stillman WS, Colagiovanni DB, Henry A. 1992. Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocytic/macrophage colony-stimulating factor in vitro. Proc. Natl. Acad. Sci. USA 89:3691-95
151. Hazel BA, O'Connor A, Niculescu R, Kalf GF. 1995. Benzene and its metabolite, hydroquinone, induce granulocytic differentiation in myeloblasts by interacting with cellular signaling pathways activated by granulocytic colony-stimulating factor. Stem Cells 13:295-310
152. Obeid LM, Linardic CM, Karolak LA, Hannun YA. 1993. Programmed cell death induced by ceramide. Science 259:1769-71
153. Suzuki YJ, Forman HJ, Sevanian A. 1997. Oxidants as stimulators of signal transduction. Free Radic. Biol. Med. 22:269-85
154. Deleted in proof
155. Monks TJ, Bratton SB, Lau SS. 1997 Metabolism and toxicity of quinone-thioethers in HL-60 cells. Fund. Appl. Toxicol. 36:255 (Abstr.)
156. Mizushima N, Koike R, Kohsaka H, Kushi Y, Handa S, et al. 1996. Ceramide induces apoptosis via CPP32 activation. FEBS Lett. 395:267-71
157. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, et al. 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37-43
158. Deleted in proof
159. Yang Z, Costanzo M, Golde DW, Kolesnik RN. 1993. Tumor necrosis factor activation of the sphingomyelinase pathway signals nuclear factor kappa B translocation in intact HL-60 cells. J. Biol. Chem. 268:20520-23
160. Collins T, Williams A, Johnson G, Kim J, Eddy R, et al. 1991. Structure and chromosomal location of the gene for endothelial-leukocyte adhesion molecule. J. Biol. Chem. 266:2466-73
161. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, et al. 1990. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344:254-57
162. Westwick JK, Bielawska AE, Dbaibo G, Hannun YA, Brenner DA. 1995. Ceramide activates the stress-activated protein kinases. J. Biol. Chem. 270:22689-92
163. Verheij M, Bose R, Lin X-H, Jarvis WD, Grant S, et al. 1996, Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380:75-79
164. 3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res. 56:3570-76
165. Naumovski L, Cleary M. 1994. Bcl2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells. Blood 83:2261-67
166. Hockenberry DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ. 1993. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241-50
167. Ishikawa T, Müller M, Klünemann C, Schaub T, Keppler D. 1990. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J. Biol. Chem. 265:19279-86
168. Ishikawa T. 1992. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci. 17:463-68
169. Brightman MW, Reese TS. 1969. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 40:648-77
170. Oldendorf WH, Brown WJ. 1975. Greater number of capillary endothelial mitochondria in brain than in muscle. Proc. Soc. Exp. Biol. Med. 149:736-38
171. Schlosshauer B. 1993. The blood-brain barrier: morphology, molecules and neurothelin. BioEssays 15:341-46
172. Spector R, Johanson CE. 1989. The mammalian choroid plexus. Sci. Am. Nov., pp. 68-74
173. Vorherr H. 1974. The Breast. Morphology, Physiology, and Lactation. New York: Academic
174. Peters MM, Jones TW, Monks TJ, Lau SS. 1997. Cytotoxicity and cell proliferation induced by the nephrocarcinogen hydroquinone, and its nephrotoxic metabolite 2,3,5-tris-(glutathion-S-yl)hydroquinone. Carcinogenesis 18: 2393-2401
175. Augusteyn RC. 1981. Protein modification of cataract: possible oxidative mechanisms. In Mechanisms of Cataract Formation in the Human Lens, ed. G Duncan, p. 71-115. London: Academic
176. Spector A. 1984. Towards a solution of senile cataracts. Invest. Opthamol. Vis. Sci. 25:130-46
177. Pethig R, Gascoyne PRC, McLaughlin JA, Szent-Gyorgi A. 1983. Ascorbate-quinone interactions: electrochemical, free radical, and cytotoxic properties. Proc. Natl. Acad. Sci. USA 80:129-32
178. Wolff SP, Spector A. 1987. Pro-oxidant activation of ocular reductants. 2. Lens epithelial cell cytotoxicity of a dietary quinone is associated with a stable free radical formed with glutathione in vitro. Exp. Eye Res. 45:791-801
179. Takahashi N, Schreiber J, Fischer V, Mason R. 1987. Formation of glutathione-conjugated semiquinones by the reaction of quinones with glutathione; an ESR study. Arch. Biochem. Biophys. 252:41-48
180. Rao DNR, Takahashi N, Mason RP. 1988. Characterization of a glutathione conjugate of the 1,4-benzosemiquinone-free radical formed in rat hepatocytes. J. Biol. Chem. 263:17981-86
181. Rees JR, Pirie A. 1967 Possible reactions of 1,2-naphthoquinone in the eye. Biochem. J. 102:853-63
182. Wells PG, Wilson B, Lubek BM. 1989 In vivo murine studies on the biochemical mechanism of naphthalene cataractogenesis. Toxicol. Appl. Pharmacol. 99:466-73
183. Hinson JA, Monks TJ, Highet RJ, Hong M, Pohl LR. 1982. 3-(Glutathion-S-yl) acetaminophen. A biliary metabolite of acetaminophen. Drug Metab. Disp. 10:47-50
184. Shichi H, Gaasterland D, Jensen NM, Nebert DW. 1978. An locus: genetic differences in susceptibility to cataracts induced by acetaminophen. Science 200:539-41
185. Shichi H, Tanaka M, Jensen NM, Nebert DW. 1980. Genetic differences in cataract and other ocular abnormalities induced by paracetamol and naphthalene. Pharmacology 20:229-41
186. Lubek BM, Avaria M, Basu PK, Wells PG. 1988. Pharmacological studies on the in vivo cataractogenicity of acetaminophen in mice and rabbits. Fundam. Appl. Toxicol. 10:596-606
187. Lubek BM, Basu PK, Wells PG. 1988. Metabolic evidence for the involvement of enzymatic bioactivation in the cataractogenicity of acetaminophen in genetically susceptible (C57BL/6) and resistant (DBA/2) murine strains. Toxicol. Appl. Pharmacol. 94:487-95